Carlos Ricotti, MD
Dermatopathology · Miami, FLNPI 1497956569
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $450, 2.9 times the $153 reported in 2019.
Across 31 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$115
- Lilly USA, LLC$108
- Galderma Laboratories, L.p.$84
- E.r. Squibb & Sons, L.L.C.$78
- Johnson & Johnson$76
- Cipher Pharmaceuticals US LLC$59
- plus $265 from 8 others
Across 2 payments — averaging $28,803 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$58K
What the payments were for
- Food & beverage$785100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Lilly USA, LLC | 4 | $108 |
| Galderma Laboratories, L.p. | 4 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Johnson & Johnson | 3 | $76 |
| Cipher Pharmaceuticals US LLC | 1 | $59 |
| Incyte Corporation | 2 | $56 |
| Ardelyx, Inc. | 3 | $55 |
| Novartis | 2 | $38 |
| Strata Skin Sciences, Inc. | 2 | $34 |
| Evoke Pharma, Inc. | 2 | $28 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$115
How this compares
$785 in reported general payments places this provider in the 70th percentile of 62 dermatopathology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 34 | $1,590 |
| Clindamycin Phosphate | 18 | $335 |
| Mupirocin | 36 | $311 |
| Ketoconazole | 29 | $222 |
| Triamcinolone Acetonide | 29 | $141 |
| Hydrocortisone | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Miami
- George ElgartMiami$559
- Rishi PatelBrooksville$38K
- John MillnsTampa$8K
- Daniel RivlinMiami Beach$3K
- Allison ArthurOrlando$3K
- Mustafa MohammadTampa$3K
- Andras SchafferTallahassee$3K
- Mazen DaoudFort Myers$2K
- Michael HennerMount Dora$2K
- Wonwoo ShonGainesville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.